Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

The stock's fall snapped a four-day winning streak.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The monthly “Google System Release Notes” primarily detail what’s new in Play services, Play Store, and Play system update across Android phones/tablets, Wear OS, Google/Android TV ...

Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks ... trend in the post-pandemic era. Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on ...

Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks ... best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them.

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...

Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.2% of Oncternal Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Vertex ...